For some with prostate cancer, a biomarker test called Decipher may help predict if their cancer will spread elsewhere in the body. Using data from an NCI-sponsored clinical trial, researchers found that people with higher Decipher scores were more likely to have cancer spread years later and to die from the disease. The test could help determine whether hormone therapy is needed.
Naproxen may be a new option for preventing colorectal cancer in people at high risk, according to results from a study of 80 people with Lynch syndrome. Naproxen is an over-the-counter drug also known as Aleve that has been on the market for years.
A new radiopharmaceutical drug called 177Lu-PSMA-617 may be an option for treating advanced prostate cancer. In a large clinical trial, adding the drug to standard treatments improved how long participants lived.
This section of NCI’s Fiscal Year 2023 Annual Plan & Budget Proposal explains how NCI is reimagining the clinical trial enterprise so that clinical research is available to people wherever they are. With additional investments, NCI can support more research to expand telemedicine into clinical trials, increase access to trials for underserved communities, and incorporate methods that simplify enrollment and data collection.
In a large clinical trial, people with HR-positive, HER2-negative metastatic breast cancer treated with ribociclib (Kisqali) and letrozole (Femara) as their first treatment lived about 1 year longer than women treated with letrozole only.
Clinical Trials Information for Patients and Caregivers
Experts review clinical trial protocols before studies are launched to make sure that they are based on sound science. All clinical trials that are funded by the federal government must go through this type of review.
Most clinical trials run as planned from beginning to end. But sometimes trials are stopped early. This page discusses some of the reasons why clinical trials might end early.
This phase 1 trial will test CAR T-cell therapy that targets a cell-surface protein called GPC3 found on the cells of advanced liver cancer. People with liver cancer that tests positive for GPC3 and that has not improved with chemotherapy will undergo the immunotherapy procedure. Doctors want to see if CAR T-cell therapy using T cells genetically modified to recognize GPC3 is safe.
This phase 3 trial will test how well chemotherapy and radiation therapy work with or without the immunotherapy drug atezolizumab (Tecentriq) for treating people with localized muscle-invasive bladder cancer. Doctors want to see if adding atezolizumab to chemoradiotherapy improves the bladder preservation, overall survival, and duration of complete responses.
This phase 3 trial studies how well axillary lymph node reverse mapping works in preventing the swelling of lymph nodes (lymphedema) in people with breast cancer who have the lymph nodes removed from under their arm. Axillary reverse mapping may help to preserve the lymph node drainage system around the breast to prevent lymphedema after surgery.
